Compare e l f Beauty Inc (ELF) vs 10X Genomics Inc (TXG) Price & Performance

ELF Beauty trades at $74.77, up 3.49% with a bullish technical signal supported by moving averages. The company shows strong revenue growth reaching $1.31B in 2025 but faces margin compression with net income margin at 1.61%. Recent earnings beats and analyst coverage skewed toward buy/hold suggest cautious optimism. Technical indicators show support at $73 and resistance at $76, with RSI neutral but ADX signaling strong trend momentum.

Outlook remains mixed: growth initiatives in skincare and international markets provide upside, but high P/E of 168.68 and margin pressures pose valuation risks. Analyst consensus target of $74.42 aligns with current price, indicating limited near-term upside. Key risks include competitive pressures and execution on brand expansion.

10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.

While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.